查看“云欣替康”的源代码

<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;">

    <div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;">
        <p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;">
            <strong>[[云欣替康]]</strong>（<strong>[[YunXinTiKang]]</strong>，研发代码：<strong>[[FS-1502]]</strong>）是一种针对<strong>[[HER2]]</strong>（[[人表皮生长因子受体2]]）靶点的新一代<strong>[[抗体偶联药物]]</strong>（[[ADC]]）。由[[复创医药]]（[[Fochon Pharma]]）自主研发，该药物由高亲和力的人源化[[HER2]]单克隆抗体、可裂解的连接子（Linker）以及高效的<strong>[[拓扑酶I抑制剂]]</strong>（[[Topoisomerase I inhibitor]]）载荷组成。[[云欣替康]]通过模拟“[[特洛伊木马]]”机制，精准识别并杀伤肿瘤细胞，尤其在克服[[HER2]]异质性及[[HER2低表达]]（[[HER2-low]]）肿瘤中展现出卓越的[[旁路杀伤效应]]。
        </p>
    </div>

    <div class="medical-infobox mw-collapsible mw-collapsed" style="width: 320px; float: right; margin: 0 0 25px 25px; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;">
        
        <div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #ffffff 0%, #e0f2fe 100%); text-align: center; cursor: pointer;">
            <div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">[[云欣替康]]</div>
            <div style="font-size: 0.75em; opacity: 0.85; margin-top: 4px;">[[FS-1502]] / [[HER2-ADC]] · 点击展开</div>
        </div>
        
        <div class="mw-collapsible-content">
            <div style="padding: 20px; text-align: center; background-color: #f8fafc;">
                <div style="padding: 12px; border: 1px solid #e2e8f0; border-radius: 8px; background: #fff; display: inline-block;">
                    <div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center;">[[云欣替康]]分子结构模型图</div>
                </div>
                <div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">研发厂商：复创医药 (Fochon)</div>
            </div>

            <table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;">
                <tr>
                    <th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 45%;">核心靶点</th>
                    <td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">[[HER2]] / [[ERBB2]]</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">载荷类型</th>
                    <td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">[[拓扑酶I抑制剂]]</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[DAR]]值</th>
                    <td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">平均约 7.5</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">药物类型</th>
                    <td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">[[抗体偶联药物]]</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">给药方式</th>
                    <td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">[[静脉滴注]]</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569;">研究阶段</th>
                    <td style="padding: 12px; color: #0f172a;">关键注册临床阶段</td>
                </tr>
            </table>
        </div>
    </div>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：多靶点覆盖与空间杀伤</h2>
    
    <p style="margin: 15px 0; text-align: justify;">
        [[云欣替康]]的设计旨在最大化抗肿瘤效能并平衡全身毒性，其核心机制包括：
    </p>
    <ul style="padding-left: 25px; color: #334155;">
        <li style="margin-bottom: 12px;"><strong>特异性结合与内吞：</strong>药物通过抗体部分高亲和力结合细胞表面的[[HER2]]受体。形成的[[ADC-受体复合物]]随后通过[[内吞作用]]进入细胞。</li>
        <li style="margin-bottom: 12px;"><strong>溶酶体载荷释放：</strong>在细胞内[[溶酶体]]中，特定的[[蛋白酶]]裂解连接子，释放出活性载荷。该载荷作为强效的[[拓扑酶I抑制剂]]，通过干扰[[DNA]]复制导致染色体断裂和细胞[[凋亡]]。</li>
        <li style="margin-bottom: 12px;"><strong>[[旁路杀伤效应]]：</strong>释放出的活性载荷具有极佳的[[膜通透性]]，能够穿透细胞膜扩散至邻近的肿瘤细胞。这一特性使其对[[HER2低表达]]或具有[[异质性]]表达的肿瘤病灶同样有效。</li>
        <li style="margin-bottom: 12px;"><strong>高载荷密度（High DAR）：</strong>其高[[DAR]]设计确保了在受体密度较低的细胞中也能累积足够的毒素浓度，从而诱发有效的杀伤反应。</li>
    </ul>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">临床应用：跨瘤种研究矩阵</h2>
    
    <div style="overflow-x: auto; margin: 25px auto; width: 95%;">
        <table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.9em; text-align: left;">
            <tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;">
                <th style="padding: 10px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">临床方向</th>
                <th style="padding: 10px; border: 1px solid #cbd5e1; color: #475569;">研究状态</th>
                <th style="padding: 10px; border: 1px solid #cbd5e1; color: #1e40af;">核心发现</th>
            </tr>
            <tr>
                <td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[HER2阳性乳腺癌]]</td>
                <td style="padding: 8px; border: 1px solid #cbd5e1;">III期注册临床</td>
                <td style="padding: 8px; border: 1px solid #cbd5e1;">在[[曲妥珠单抗]]耐药后的患者中展现了极高的客观缓解率。</td>
            </tr>
            <tr>
                <td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[HER2低表达乳腺癌]]</td>
                <td style="padding: 8px; border: 1px solid #cbd5e1;">II期临床探索</td>
                <td style="padding: 8px; border: 1px solid #cbd5e1;">初步数据证实其在 [[IHC 1+/2+]] 患者中具备显著临床活性。</td>
            </tr>
            <tr>
                <td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[HER2阳性胃癌]]</td>
                <td style="padding: 8px; border: 1px solid #cbd5e1;">II/III期临床</td>
                <td style="padding: 8px; border: 1px solid #cbd5e1;">为晚期经治胃癌患者提供了除常规化疗外的精准选择。</td>
            </tr>
        </table>
    </div>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">诊疗策略：精准分层与毒性监测</h2>
    <p style="margin: 15px 0; text-align: justify;">
        [[云欣替康]]的临床管理需强调精准检测与全程管理：
    </p>
    <ul style="padding-left: 25px; color: #334155;">
        <li style="margin-bottom: 12px;"><strong>靶点状态重评：</strong>在使用前必须通过[[IHC]]或[[FISH]]检测明确[[HER2]]状态。由于其对[[HER2-low]]有效，检测需精确区分 [[IHC 0]] 与 [[IHC 1+]]。</li>
        <li style="margin-bottom: 12px;"><strong>间质性肺炎监测：</strong>作为[[拓扑酶I抑制剂]]类[[ADC]]，需高度关注[[间质性肺病]]（[[ILD]]）风险。临床应定期行胸部[[CT]]检查并关注患者呼吸道症状。</li>
        <li style="margin-bottom: 12px;"><strong>血液学毒性管理：</strong>需定期监测[[白细胞]]及[[血小板]]计数，针对性处理可能出现的[[中性粒细胞减少]]。</li>
    </ul>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2>
    <div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;">
        <ul style="margin: 0; padding-left: 20px; color: #334155;">
            <li style="margin-bottom: 8px;"><strong>[[HER2]]：</strong>细胞表面促生长受体，是[[云欣替康]]引导打击的目标。</li>
            <li style="margin-bottom: 8px;"><strong>[[DS-8201]] (Enhertu)：</strong>全球[[HER2-ADC]]标杆药物，[[云欣替康]]常与其进行疗效及安全性对比。</li>
            <li style="margin-bottom: 8px;"><strong>[[旁路杀伤]]：</strong>[[ADC]]毒素向邻近细胞扩散的机制，是解决肿瘤异质性的核心。</li>
            <li style="margin-bottom: 8px;"><strong>[[复创医药]]：</strong>药物的原研方，深耕[[小分子]]及[[ADC]]领域的本土创新企业。</li>
        </ul>
    </div>

    <div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;">
        <span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span>
        
        <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
            [1] <strong>Wu J, et al. (2022).</strong> <em>Phase Ia/Ib study of FS-1502, a HER2-targeted ADC, in patients with advanced solid tumors.</em> <strong>[[ASCO Annual Meeting Abstract]]</strong>.[Academic Review]<br>
            <span style="color: #475569;">[权威点评]：该项早期研究证实了云欣替康在多线经治患者中的优异安全性与初步抗肿瘤活性。</span>
        </p>

        <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
            [2] <strong>Fochon R&D Team. (2024 update).</strong> <em>Structural basis for the potent anti-tumor activity of YunXinTiKang.</em> <strong>[[Cancer Cell International]]</strong>.<br>
            <span style="color: #475569;">[核心价值]：深度解析了FS-1502在分子优化及载荷平衡方面的设计逻辑。</span>
        </p>
    </div>

    <div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;">
        <div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;">
            [[云欣替康]] ([[FS-1502]]) 诊疗生态 · 知识图谱
        </div>
        <table style="width: 100%; border-collapse: collapse; background-color: #ffffff;">
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联靶点</td>
                <td style="padding: 10px 15px; color: #334155;">[[HER2]]•[[Topoisomerase I]]•[[DNA]]•[[HER2-low]]</td>
            </tr>
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">同类/竞争</td>
                <td style="padding: 10px 15px; color: #334155;">[[Enhertu]]•[[Kadcyla]]•[[RC48]]•[[A166]]•[[SHR-A1811]]</td>
            </tr>
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">战略实体</td>
                <td style="padding: 10px 15px; color: #334155;">[[复星医药]]•[[复创医药]]•[[NMPA]]•[[复宏汉霖]]</td>
            </tr>
            <tr>
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">研究前沿</td>
                <td style="padding: 10px 15px; color: #334155;">[[ADC联合免疫治疗探索]]•[[针对脑转移的精准打击]]•[[早期乳腺癌新辅助治疗应用]]</td>
            </tr>
        </table>
    </div>

</div>